About the Company
We do not have any company description for 4D Molecular Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate ...
Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts
Across the recent three months, 5 analysts have shared their insights on 4D Molecular Therapeutics FDMT, expressing a variety of opinions spanning from bullish to bearish. The table below offers a ...
4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape
D Molecular Therapeutics, Inc. (FDMT) has disclosed a new risk, in the Sales & Marketing category. 4D Molecular Therapeutics, Inc. faces ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue ...
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago.
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics ... - Nasdaq
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average target of $30.33, a high estimate of $46.00, and a low estimate of $6.00.
Analyst Expectations For 4D Molecular Therapeutics's Future
Discovering 4D Molecular Therapeutics: A Closer Look 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and ...
4D Molecular Therapeutics, Inc. (FDMT) Special Call Transcript
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Special Call July 17, 2024 6:30 AM ETCompany ParticipantsUneek Mehra - Chief Financial and Business ...
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances
4D Molecular Therapeutics, Inc., a clinical-stage genetic medicines company, is focused on developing innovative therapies for large market diseases in ophthalmology and pulmonology using its ...
4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On ...
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a small biotechnology company developing treatments for lung diseases, macular degeneration, and other ailments.
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results ...
EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...
Similar Companies
Loading the latest forecasts...